University of Bologna Sant Orsola Malpighi
Welcome,         Profile    Billing    Logout  
 4 Trials 
13 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Palandri, Francesca
MANIFEST-2, NCT04603495 / 2020-001989-10: Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF)

Jan 2024 - Dec 2024: Approval for myelofibrosis
Hourglass Jul 2024 - Dec 2024 : Regulatory submission in EU for 1L myelofibrosis
Jan 2024 - Mar 2024: From MANIFEST-2 trial in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis
Feb 2024 - Feb 2024: Completion of P2b trial for JIA
Feb 2024 - Feb 2024: Exclusivity expiry in US
Active, not recruiting
3
430
Europe, Canada, US, RoW
Pelabresib, Ruxolitinib, Placebo
Constellation Pharmaceuticals
Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
08/23
12/27
ROP-ET, NCT06514807: A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients

Active, not recruiting
3
117
Europe, RoW
Ropeginterferon alfa-2b (BESREMi®)
AOP Orphan Pharmaceuticals AG
Essential Thrombocythaemia
03/28
03/28
SENTRY, NCT04562389: Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis

Checkmark Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022
Hourglass Dec 2022 - Dec 2022 : Data from trial in combination with ruxolitinib myelofibrosis
Checkmark Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022
More
Recruiting
3
350
Europe, Canada, US, RoW
Selinexor, KPT-330, Placebo, Ruxolitinib
Karyopharm Therapeutics Inc
Myelofibrosis
09/25
03/28
MYLOX-1, NCT04679870 / 2020-003087-45: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis

Active, not recruiting
2
21
Europe, US, RoW
GB2064
Galecto Biotech AB, OPIS s.r.l
Myelofibrosis
12/23
06/26
POTAMI-61, NCT06397313: RVU120 in Patients with Intermediate or High-risk, Primary or Secondary Myelofibrosis

Recruiting
2
230
Europe
RVU120, SEL120, Ruxolitinib, RUX
Ryvu Therapeutics SA
Myelofibrosis
06/26
10/27
NCT04562870 / 2020-003809-60: A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants with Previously Treated Myelofibrosis

Hourglass Jul 2023 - Dec 2023 : Top-line data from XPORT-MF-035 trial for myelofibrosis
Checkmark First patient dosed as a monotherapy in patients with 2L myelofibrosis
Dec 2021 - Dec 2021: First patient dosed as a monotherapy in patients with 2L myelofibrosis
Active, not recruiting
2
112
Europe, US, RoW
Selinexor, Physician's Choice Treatment
Karyopharm Therapeutics Inc
Myelofibrosis
01/25
01/25
SENTRY-2, NCT05980806: A Study of Selinexor Monotherapy in Subjects with JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

Recruiting
2
118
Europe, Canada, US, RoW
Selinexor 60 mg, KPT-330, Selinexor 40 mg, Ruxolitinib, JAKAFI, Pacritinib, VONJO, Momelotinib, OJJAARA
Karyopharm Therapeutics Inc
Myelofibrosis, Moderate Thrombocytopenia
04/26
10/28
PV-ARC, NCT06134102: Clinical and Laboratory Characteristics of Polycythemia Vera

Completed
N/A
1150
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Polycythemia Vera
12/23
12/23
MPN-COVID, NCT04385160: Myeloproliferative Neoplasms (MPN) and COVID-19

Recruiting
N/A
552
Europe, US, RoW
Fondazione per la Ricerca Ospedale Maggiore, European Leukemia Net
Myeloproliferative Neoplasm, COVID
02/22
08/22
RUX-MF, NCT06516406: Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera

Recruiting
N/A
1055
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Myelofibrosis, Primary Myelofibrosis, Secondary Myelofibrosis
05/32
05/32
NCT06506084: Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV)

Recruiting
N/A
319
Europe
Ropeginterferon alfa-2b, Besremi
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Polycythemia Vera
09/26
12/26
ERNEST-3, NCT06533813: Clinical Epidemiology in Contemporary Patients With Myelofibrosis.

Recruiting
N/A
617
Europe, RoW
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS, GlaxoSmithKline
Myelofibrosis
12/25
12/28
NCT05553873: Evaluation of Inflammatory Markers in ph Negative Myeloproliferative Neoplasms: Impact on Outcome and Response to Therapy. Multicenter Retro-prospective Observational Study. The INFLA-ME (INFLAmmation in Myeloproliferative Disease) Study.

Recruiting
N/A
500
Europe
University of Milano Bicocca
Myeloproliferative Disease, Inflammatory Markers
12/26
12/26

Download Options